Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat models

Molecular Pharmacology

Volumn 84, Issue 1, 2013, Pages 62-70

  Shimozono, Rieko ^a   Asaoka, Yoshiji ^a   Yoshizawa, Yoshitaka ^a   Aoki, Takumi ^a   Noda, Hidetoshi ^a   Yamada, Masateru ^a   Kaino, Mie ^a   Mochizuki, Hidenori ^a  

^a TORAY INDUSTRIES INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

[1 [5 (FURAN 2 YL) 1,3,4 OXADIAZOL 2 YL] 3 (PYRIDIN 2 YLMETHYL)UREA]; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; NK 252; OLTIPRAZ; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DIET; DISEASE COURSE; GENE EXPRESSION; HISTOPATHOLOGY; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER PROTECTION; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

AMINO ACIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BINDING SITES; CELL LINE; CHOLINE; DIET; DIHYDROPYRIDINES; DIOXINS; DISEASE PROGRESSION; DOWN-REGULATION; FATTY LIVER; FIBROSIS; GENE EXPRESSION; HUMANS; HYDROGEN PEROXIDE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; MALE; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; RATS; TRANSAMINASES; UP-REGULATION;

EID: 84879090781     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.084269     Document Type: Article

References (40)

1. Blight KJ, McKeating JA, and Rice CM (2002) Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76:13001-13014.
2. Brooks SC, 3rd, Brooks JS, Lee WH, Lee MG, and Kim SG (2009) Therapeutic potential of dithiolethiones for hepatic diseases. Pharmacol Ther 124:31-43.
3. Brunt EM (2001) Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 21:3-16.
4. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, and Sanyal AJ (2012) The diagnosis and management of non-Alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:2005-2023.
5. Chowdhry S, Nazmy MH, Meakin PJ, Dinkova-Kostova AT, Walsh SV, Tsujita T, Dillon JF, Ashford ML, and Hayes JD (2010) Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic Biol Med 48:357-371.
6. Comar KM and Sterling RK (2006) Review article: Drug therapy for non-Alcoholic fatty liver disease. Aliment Pharmacol Ther 23:207-215.
7. De Bleser PJ, Xu G, Rombouts K, Rogiers V, and Geerts A (1999) Glutathione levels discriminate between oxidative stress and transforming growth factor-beta signaling in activated rat hepatic stellate cells. J Biol Chem 274:33881-33887.
8. Fon Tacer K and Rozman D (2011) Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation. J Lipids 2011:783976.
9. García-Trevijano ER, Iraburu MJ, Fontana L, Domínguez- Rosales JA, Auster A, Covarrubias-Pinedo A, and Rojkind M (1999) Transforming growth factor beta1 induces the expression of alpha1(I) procollagen mRNA by a hydrogen peroxide-C/EBPbeta-dependent mechanism in rat hepatic stellate cells. Hepatology 29:960-970.
10. Gupte AA, Liu JZ, Ren Y, Minze LJ, Wiles JR, Collins AR, Lyon CJ, Pratico D, Finegold MJ, and Wong ST et al. (2010) Rosiglitazone attenuates age-And dietassociated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice. Hepatology 52:2001-2011.
11. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, and Hatayama I et al. (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236:313-322.
12. Itoh K, Tong KI, and Yamamoto M (2004) Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radic Biol Med 36:1208-1213.
13. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, and Yamamoto M (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13:76-86.
14. Kang KW, Kim YG, Cho MK, Bae SK, Kim CW, Lee MG, and Kim SG (2002) Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation. FASEB J 16:1988-1990.
15. Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, and Okita K (2004) Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-Altered lesions in rat liver cirrhosis induced by a choline-deficient L-Amino acid-defined diet. Biochem Biophys Res Commun 315:187-195.
16. Kim SG, Kim YM, Choi JY, Han JY, Jang JW, Cho SH, Um SH, Chon CY, Lee DH, and Jang JJ et al. (2011) Oltipraz therapy in patients with liver fibrosis or cirrhosis: a randomized, double-blind, placebo-controlled phase II trial. J Pharm Pharmacol 63:627-635.
17. Kobayashi M, Li L, Iwamoto N, Nakajima-Takagi Y, Kaneko H, Nakayama Y, Eguchi M, Wada Y, Kumagai Y, and Yamamoto M (2009) The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Mol Cell Biol 29:493-502.
18. Koek GH, Liedorp PR, and Bast A (2011) The role of oxidative stress in non-Alcoholic steatohepatitis. Clin Chim Acta 412:1297-1305.
19. Konwinski RR, Haddad R, Chun JA, Klenow S, Larson SC, Haab BB, and Furge LL (2004) Oltipraz, 3H-1,2-dithiole-3-thione, and sulforaphane induce overlapping and protective antioxidant responses in murine microglial cells. Toxicol Lett 153: 343-355.
20. Kwak MK, Itoh K, Yamamoto M, Sutter TR, and Kensler TW (2001) Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3- thione. Mol Med 7:135-145.
21. Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M, and Kensler TW (2003) Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem 278:8135-8145.
22. Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJ, Benyon C, and Iredale JP (2002) Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 277:11069-11076.
23. Nakae D, Yoshiji H, Mizumoto Y, Horiguchi K, Shiraiwa K, Tamura K, Denda A, and Konishi Y (1992) High incidence of hepatocellular carcinomas induced by a choline deficient L-Amino acid defined diet in rats. Cancer Res 52:5042-5045.
24. Nioi P, McMahon M, Itoh K, Yamamoto M, and Hayes JD (2003) Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P) H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. Biochem J 374:337-348
25. Oh CJ, Kim JY, Min AK, Park KG, Harris RA, Kim HJ, and Lee IK (2012) Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-b/Smad signaling. Free Radic Biol Med 52:671-682.
26. Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M, Kang MI, Kobayashi A, Yokoyama S, and Yamamoto M (2006) Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 21:689-700.
27. Reisman SA, Aleksunes LM, and Klaassen CD (2009a) Oleanolic acid activates Nrf2 and protects from acetaminophen hepatotoxicity via Nrf2-dependent and Nrf2-independent processes. Biochem Pharmacol 77:1273-1282.
28. Reisman SA, Buckley DB, Tanaka Y, and Klaassen CD (2009b) CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes. Toxicol Appl Pharmacol 236:109-114.
29. Roberts AB, Tian F, Byfield SD, Stuelten C, Ooshima A, Saika S, and Flanders KC (2006) Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 17:19-27.
30. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, and Unalp A et al.; NASH CRN (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362:1675-1685.
31. Shin S, Wakabayashi J, Yates MS, Wakabayashi N, Dolan PM, Aja S, Liby KT, Sporn MB, Yamamoto M, and Kensler TW (2009) Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. Eur J Pharmacol 620:138-144.
32. Sies H (1997) Oxidative stress: oxidants and antioxidants. Exp Physiol 82:291-295.
33. Sreekumar R, Rosado B, Rasmussen D, and CharltonM(2003) Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 38:244-251.
34. Sugimoto H, Okada K, Shoda J, Warabi E, Ishige K, Ueda T, Taguchi K, Yanagawa T, Nakahara A, and Hyodo I et al. (2010) Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 298:G283-G294.
35. Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, and Yamamoto M (2006) Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol Cell Biol 26:2887-2900.
36. Valenti L, Rametta R, Dongiovanni P, Maggioni M, Fracanzani AL, Zappa M, Lattuada E, Roviaro G, and Fargion S (2008) Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes 57: 1355-1362.
37. Vernon G, Baranova A, and Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-Alcoholic fatty liver disease and non-Alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274-285.
38. Verrecchia F, Chu ML, and Mauviel A (2001) Identification of novel TGF-beta /Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 276:17058-17062.
39. Yu Z, Shao W, Chiang Y, Foltz W, Zhang Z, Ling W, Fantus IG, and Jin T (2011) Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 [corrected] (NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice. Diabetologia 54:922-934.
40. Zhang YK, Yeager RL, Tanaka Y, and Klaassen CD (2010) Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine-And cholinedeficient diet. Toxicol Appl Pharmacol 245:326-334.